Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Myriad Genetics Inc.

    NASDAQ: MYGN · Real-Time Price · USD
    5.53
    -0.18 (-3.15%)
    At close: Aug 19, 2025, 3:59 PM
    5.58
    0.98%
    After-hours: Aug 19, 2025, 06:17 PM EDT
    -3.15%
    Bid 5.52
    Market Cap 514.07M
    Revenue (ttm) 831.3M
    Net Income (ttm) -101.4M
    EPS (ttm) -4.31
    PE Ratio (ttm) -1.28
    Forward PE 52.46
    Analyst Hold
    Ask 6.5
    Volume 1,004,749
    Avg. Volume (20D) 1,972,898
    Open 5.69
    Previous Close 5.71
    Day's Range 5.51 - 5.83
    52-Week Range 3.76 - 29.30
    Beta 1.90

    About MYGN

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol MYGN
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for MYGN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Myriad Genetics Inc. is scheduled to release its earnings on Nov 6, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 week ago
    +46.51%
    Myriad Genetics shares are trading higher after th... Unlock content with Pro Subscription
    2 weeks ago
    -2.76%
    Myriad Genetics shares are trading higher after the company reported better-than-expected Q2 EPS and sales.
    news image

    1 week ago · seekingalpha.com

    Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth

    Myriad Genetics posted Q2 2025 revenue growth of 1% year-over-year, but adjusted for one-time events, growth would have been 5%. Key growth drivers include expanding Hereditary Cancer Testing to unaff...

    news image

    1 week ago · seekingalpha.com

    Myriad Genetics, Inc. (MYGN) Q2 2025 Earnings Call Transcript

    Myriad Genetics, Inc. (NASDAQ:MYGN ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Mark S. Verratti - Chief Operating Officer Matthew Scalo - Senior Vice President of...

    news image

    2 weeks ago · fool.com

    Myriad Genetics (MYGN) Q2 Revenue Up 6%

    Myriad Genetics (MYGN) Q2 Revenue Up 6%

    news image

    2 weeks ago · zacks.com

    Compared to Estimates, Myriad (MYGN) Q2 Earnings: A Look at Key Metrics

    The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates ...

    news image

    2 weeks ago · zacks.com

    Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates

    Myriad Genetics (MYGN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to earnings of $0.05 per share a year ago.

    news image

    2 months ago · zacks.com

    Should You Hold Myriad Genetics Stock in Your Portfolio Right Now?

    MYGN sees growth in oncology and women's health testing, but GeneSight coverage loss clouds the near-term outlook.

    news image

    2 months ago · zacks.com

    Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue?

    Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?

    news image

    2 months ago · accessnewswire.com

    Levi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) Over Possible Securities Fraud

    NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning p...

    news image

    2 months ago · accessnewswire.com

    Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation

    NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "...

    news image

    2 months ago · accessnewswire.com

    Ongoing Myriad Genetics, Inc. (MYGN) Investigation: Protect Your Rights - Contact Levi & Korsinsky

    NEW YORK, NY / ACCESS Newswire / May 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning p...

    Add to Watchlist